Amgen: all 1,085 studies
Page 8 of 11. Open to participants first (51), then studies with results posted, then the rest; newest registration first within each.
- A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.TerminatedNCT05322577Phase 1/2
- A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor IndicationsTerminatedNCT05317078Phase 1
- EVOLVE-MI: EVOLocumab Very Early After Myocardial InfarctionActive, not recruitingNCT05284747Phase 4
- AMG 701 Expanded Access ProgramNo longer availableNCT05256446
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Phase 3
- A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Active, not recruitingNCT05094336Phase 1/2
- A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)Active, not recruitingNCT05060016Phase 2
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Phase 3
- TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement StudyCompletedNCT05002998Phase 4
- A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)WithdrawnNCT04998747Phase 1
- Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic LeukemiaActive, not recruitingNCT04994717Phase 3
- A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic DiseasesCompletedNCT04948099Phase 1
- Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver DiseaseCompletedNCT04857606Phase 1
- Expanded Access of SotorasibNo longer availableNCT04667234
- Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the BoneActive, not recruitingNCT04586660Phase 4
- Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 InfectionTerminatedNCT04526912Phase 1
- A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLActive, not recruitingNCT04521231Phase 1/2
- A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung CancerWithdrawnNCT04466917Phase 3
- Heart Failure Study to Evaluate Vital Signs and Overcome Low Use of Guideline-Directed Therapy by Remote MonitoringTerminatedNCT04292275Not applicable
- The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)TerminatedNCT04197453
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruitingNCT04185883Phase 1
- A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque PsoriasisCompletedNCT04175613Phase 3
- Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased DonorWithdrawnNCT04174677Phase 2
- A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With OmeprazoleCompletedNCT04139226Phase 1
- Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic CancersTerminatedNCT04117958Phase 1
- Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye DiseaseApproved for marketingNCT04040894
- A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical PracticeCompletedNCT04031027
- Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast CancerActive, not recruitingNCT03937154Phase 3
- Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AMLWithdrawnNCT03904069Phase 1
- Efficacy and Safety of Erenumab in Pediatric Participants With Episodic MigraineActive, not recruitingNCT03836040Phase 3
- Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic MigraineCompletedNCT03832998Phase 3
- A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological TreatmentCompletedNCT03828045
- A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and DermatomyositisCompletedNCT03817424Phase 1
- An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder CancerNo longer availableNCT03801278
- Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPCTerminatedNCT03792841Phase 1
- Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)CompletedNCT03776058Phase 2
- A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing ChemotherapyCompletedNCT03776032Phase 3
- Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary HyperparathyroidismCompletedNCT03774771Phase 2
- A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in FranceCompletedNCT03757013
- Expanded Access for CC-10004No longer availableNCT03740516
- A Phase1 Study of VIB9600TerminatedNCT03621605Phase 1
- An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant RecipientsWithdrawnNCT03619187Phase 3
- Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)CompletedNCT03608657
- A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)CompletedNCT03600883Phase 1/2
- Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in SpainCompletedNCT03539419
- AMG 714 Expanded Access ProgramNo longer availableNCT03439475
- A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLCSuspendedNCT03392064Phase 1
- Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.WithdrawnNCT03343847Phase 3
- Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)Active, not recruitingNCT03319940Phase 1
- A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaTerminatedNCT03287908Phase 1
- Post-Marketing Surveillance Study of OTEZLACompletedNCT03284879
- Observational Study of BlinatumomabCompletedNCT03117621
- Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice ConditionsCompletedNCT03106051
- A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in BelgiumCompletedNCT03097003
- A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in BelgiumCompletedNCT03096990
- Real-world Use of Carfilzomib Among Multiple Myeloma Patients in EuropeCompletedNCT03091127
- Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United StatesCompletedNCT02993120
- Evolocumab Pregnancy Exposure RegistryTerminatedNCT02957604
- APremilast After FumaRic Acid Ester TreatmentCompletedNCT02954081
- Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic InfectionCompletedNCT02910557
- Study to Evaluate the Safety of Repatha® in PregnancyTerminatedNCT02906124
- A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The NetherlandsCompletedNCT02875184
- Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in JapanCompletedNCT02808403
- Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Auto-injector Device and Manual InjectionCompletedNCT02799498Phase 1
- Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA StudyCompletedNCT02792478
- An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the USCompletedNCT02783651
- A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune DiseasesCompletedNCT02780674Phase 1
- Chart Review of Repatha® in Subjects With HyperlipidaemiaCompletedNCT02770131
- A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology PracticeCompletedNCT02740218
- Observational Study of Apremilast in Patients With Psoriasis in The NetherlandsCompletedNCT02652494
- A Study of Otezla® in Patients With Plaque Psoriasis Under Routine ConditionsCompletedNCT02626793
- ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st LineCompletedNCT02624895
- Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection in the Thigh to Compare an Auto-injector Device and a Manual Injection in Healthy SubjectsCompletedNCT02588534Phase 1
- Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581CompletedNCT02567370Phase 1
- Denosumab Safety Assessment in Multiple Observational DatabasesCompletedNCT02520362
- Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or SchizoaffectiveCompletedNCT02504476Phase 1
- Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid ArthritisTerminatedNCT02499315Phase 1
- A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus ErythematosusCompletedNCT02443506Phase 1
- Safety Study of AMG 228 to Treat Solid TumorsTerminatedNCT02437916Phase 1
- Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial SpondyloarthritisWithdrawnNCT02429882Phase 2
- A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus ErythematosusCompletedNCT02411136Phase 1
- A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus ErythematosusCompletedNCT02391259Phase 1
- A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy SubjectCompletedNCT02348879Phase 1
- Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in FranceCompletedNCT02347865
- Phase 1b Study of CCX872-B in Patients With Pancreatic AdenocarcinomaCompletedNCT02345408Phase 1
- Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORRCompletedNCT02322736
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee PainCompletedNCT02318407Phase 1
- Historical Data Analysis of Complete Remission in Children With R/R Acute Lymphoblastic Leukemia (ALL)CompletedNCT02303522
- Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c MelanomaNo longer availableNCT02297529
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus ErythematosusCompletedNCT02291588Phase 1
- A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced MalignanciesTerminatedNCT02244112Phase 1
- Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular CarcinomaWithdrawnNCT02227914Phase 1/2
- Study of Haemodialysis Patients Switching From Aranesp to BiosimilarCompletedNCT02191150
- Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALLNo longer availableNCT02187354
- Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on DialysisCompletedNCT02185911
- Registry Study for Talimogene LaherparepvecCompletedNCT02173171
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal PolypsCompletedNCT02170337Phase 1
- Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c MelanomaNo longer availableNCT02147951
- A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric CancerTerminatedNCT02137343Phase 3
- Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine SubjectsTerminatedNCT02132429Phase 1